drugset / Trial / NCT02396433

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

NCT02396433

NaSingle-groupOpen-labelTreatment

Summary

Non-randomized, open-label, multi-center, phase I/II, dose-escalation study of the combination of carboplatin, eribulin, and E7449.

Timeline

Start
2015-04
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 2X-121 Small molecule
Subject Carboplatin Small molecule
Subject Eribulin Small molecule

Indications